Trial reportCalcified tissue international2016
Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan.
Trial report in Calcified tissue international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.Endocrine · 2018Pooled it
- Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease.Frontiers in endocrinology · 2025Trial
- Real-World Osteoporosis Pharmacotherapy in the UAE: Prescribing Trends, Adherence, and Patient Beliefs.Healthcare (Basel, Switzerland) · 2026Article
- Brazilian guidelines for the management of osteoporosis in diabetes mellitus.Diabetology & metabolic syndrome · 2025Review
- Bone metabolism in diabetes: a clinician's guide to understanding the bone-glucose interplay.Diabetologia · 2024Review
- Bone Health in Patients With Type 2 Diabetes.Journal of the Endocrine Society · 2024Article
- Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes.Current osteoporosis reports · 2024Review
- Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes.JBMR plus · 2023Review
- Biochemical Markers of Bone Fragility in Patients with DiabetesThe Journal of clinical endocrinology and metabolism · 2023Article
- Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial.Therapeutic advances in endocrinology and metabolism · 2023Article
- Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry.Aging clinical and experimental research · 2022Observational
- Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus.World journal of diabetes · 2021Review
- The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News?Journal of clinical medicine · 2021Review
- Executive summary of clinical practice guide on fracture risk in lifestyle diseases.Journal of bone and mineral metabolism · 2020Article
- Teriparatide Improves Bone and Lipid Metabolism in a Male Rat Model of Type 2 Diabetes Mellitus.Endocrinology · 2019Article
- Diabetes and bone.Osteoporosis and sarcopenia · 2019Review
- Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis.Journal of bone and mineral metabolism · 2019Article
- Diagnosis and management of bone fragility in diabetes: an emerging challenge.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018 · on this mapReview
- Clinical aspects and management of osteoporosis and fragility fractures in patients with diabetes.Osteoporosis and sarcopenia · 2017Review
- Diabetes, bone and glucose-lowering agents: clinical outcomes.Diabetologia · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many osteoporotics have comorbid diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DL). However, whether such comorbidities alter response to anti-osteoporotic treatment is unknown. We did post hoc analyses of combined data from three risedronate Japanese phase III trials to determine whether the presence of DM, HT, or DL affects its efficacy and safety. Data from 885 subjects who received 48-week treatment with risedronate were collected and combined from the three phase III trials. They were divided into two groups by the presence or absence of comorbidities: DM (n = 53) versus non-DM (n = 832); HT (n = 278) versus non-HT (n = 607); and DL (n = 292) versus non-DL (n = 593). Bone mineral density (BMD), urinary type 1 collagen N-telopeptide (uNTX), and serum bone-specific alkaline phosphatase (BAP) were measured at baseline and sequentially until 48 weeks. BMD or bone markers were not different between any of the two groups. Overall, BMD was increased by 5.52%, and uNTX and BAP were decreased by 35.4 and 33.8%, respectively. Some bone markers were slightly lower in DM and DL subjects, but the responses to risedronate were not significantly different. Statin users had lower uNTX and BAP, but showed no difference in the treatment response. All the other medications had no apparent effect. Adverse event incidence was marginally higher in DL compared with non-DL (Relative risk 1.06; 95% confidence interval 1.01-1.11), but was not related to increase in any specific events. Risedronate shows consistent safety and efficacy in suppressing bone turnover and increasing BMD in osteoporosis patients with comorbid DM, HT, and/or DL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.